Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    3
    ...
ATC Name B/G Ingredients Dosage Form Price
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 50mg 50mg Tablet, coated 1,849,127 L.L
N06AB10 ESCITALOPRAM BIOGARAN G Escitalopram (oxalate) - 20mg 20mg Tablet, coated, scored 678,640 L.L
D10AD51 ERYLIK G Tretinoin - 0.025%, Erythromycin - 4% Gel 378,964 L.L
A08AB01 ELIZA 120 G Orlistat - 120mg 120mg Capsule 1,711,159 L.L
M01AH05 ETOXA G Etoricoxib - 60mg 60mg Tablet, film coated 1,109,630 L.L
A11CC05 EURO D 10000 IU G Vitamin D3 - 10,000IU 10,000IU Capsule 993,100 L.L
D10AF02 ERYTHROMYCIN 1.5 % G Erythromycin - 15mg/ml 1.5 % Solution 501,701 L.L
J01MA14 EVAFLOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 669,234 L.L
M01AH05 ETOXA G Etoricoxib - 60mg 60mg Tablet, film coated 369,877 L.L
M01AH05 ETOXIB G Etoricoxib - 60mg 60mg Tablet, film coated 1,217,521 L.L
B03AB ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 156.25mg/5ml Syrup 279,519 L.L
B03AB05 ENRICH N G Iron trivalent (hydroxide polymaltose complex) - 50mg/ml 50mg/ml Drops 459,594 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 1,293,928 L.L
M01AH05 ETOXA G Etoricoxib - 90mg 90mg Tablet, film coated 431,309 L.L
M01AH05 ETOXIB G Etoricoxib - 90mg 90mg Tablet, film coated 1,390,877 L.L
A02BC05 ESO TAD G Esomeprazole - 20mg 20mg Capsule, hard, gastro-resistant 299,677 L.L
A11CC05 EURO D HP 50.000 IU G Vitamin D3 - 50,000IU 50,000IU Capsule 1,432,536 L.L
A02BC05 ESOCAP-UBSA G Esomeprazole - 20mg 20mg Capsule 511,940 L.L
A02BC05 ESOMEP G Esomeprazole - 20mg 20mg Tablet, gastroresistant 415,632 L.L
A02BC05 ESOMEPRAZOLE ARROW G Esomeprazole - 20mg 20mg Capsule, gastro-resistant 366,869 L.L
A02BC05 ESOMEPRAZOLE BIOGARAN G Esomeprazole (magnesium dihydrate) - 20mg 20mg Capsule, gastro-resistant 493,190 L.L
B03AD EURO-FER CF G Folic acid - 0.5mg, Vitamin C - 200mg, Ferrous fumarate - 300mg Capsule 706,861 L.L
M01AH05 ETOXA G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
A02BC05 EXONAR G Esomeprazole (magnesium trihydrate) - 20mg 20mg Capsule, delayed release 511,940 L.L
M01AH05 ETOXIB G Etoricoxib - 120mg 120mg Tablet, film coated 425,998 L.L
L01BA01 EBETREXAT G Methotrexate - 50mg/5ml 50mg/5ml Injectable solution 1,507,821 L.L
A02BC05 ESO TAD G Esomeprazole - 40mg 40mg Capsule, hard, gastro-resistant 389,714 L.L
A02BC05 ESOCAP-UBSA G Esomeprazole - 40mg 40mg Capsule 646,324 L.L
A02BC05 ESOFLUX G Esomeprazole - 40mg 40mg Capsule 646,324 L.L
    3
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025